Survodutide 10 mg

Peptide Hubs Survodutide

Introducing the next evolution in metabolic peptide therapy: Peptide Hubs Survodutide 10 mg. As the cutting-edge dual agonist targeting both GLP-1 and glucagon receptors, Survodutide represents a superior approach to body recomposition, fat loss, and metabolic health. While single GLP-1 agonists suppress appetite, Survodutide's dual mechanism amplifies results by simultaneously increasing energy expenditure—making it exceptionally effective for athletes and bodybuilders during cutting phases. This legit Peptide Hubs product is backed by rigorous third-party lab testing, confirming a potent 10.21 mg per vial. For those seeking to buy Survodutide by Peptide Hubs, you're choosing a scientifically-advanced tool to reveal hard-earned muscle definition, conquer stubborn fat, and optimize metabolic function with precision.

Survodutide Composition

Each 2 mL vial contains 10 mg of high-purity Survodutide (also known as BI 456906), a synthetic, acylated peptide engineered to act as a dual agonist for both the Glucagon-like Peptide-1 (GLP-1) receptor and the Glucagon (GCGR) receptor. It is supplied as a sterile, white lyophilized powder, ensuring maximum stability until reconstitution.

Bodybuilding & Athletic Benefits

For the physique athlete, Survodutide is a game-changing asset. Its dual-action profile delivers compounded benefits: First, through potent GLP-1 receptor activation, it dramatically reduces appetite and calorie intake, eliminating cravings and making strict dieting manageable. Second, and crucially, its glucagon receptor agonism increases resting energy expenditure and promotes hepatic fatty acid oxidation, essentially forcing the body to burn more fat for fuel. This combination leads to rapid and significant reduction in visceral and subcutaneous adipose tissue while preserving lean muscle mass—the holy grail of cutting. Users experience enhanced insulin sensitivity, improved lipid profiles, and a leaner, more vascular physique.

Therapeutic Indication

Clinically, Survodutide is under advanced investigation for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), including its inflammatory form, MASH. Phase 2 trial data has demonstrated profound weight loss efficacy and significant reduction in liver fat content. Its mechanism addresses core dysfunctions in energy balance and metabolism, positioning it as a potential frontline therapy for complex metabolic conditions. Research published in The New England Journal of Medicine highlights its promising efficacy and safety profile.

Dosage (Men)

Male users should initiate therapy with a low dose to assess tolerance. A standard protocol begins at 0.6 mg administered via subcutaneous injection once weekly. The dose can be titrated upward every 2-4 weeks based on tolerance and therapeutic response. Effective maintenance doses for fat loss often range between 2.4 mg and 4.8 mg per week. The long half-life supports convenient once-weekly dosing.

Dosage (Women)

Female users are advised to follow a similar cautious titration. Starting dose is typically 0.6 mg once weekly. Dose escalation should be gradual, with many women finding an effective maintenance dose in the range of 1.8 mg to 3.6 mg per week. Individual sensitivity to gastrointestinal side effects should guide the speed of titration.

Active Life

Survodutide has a long elimination half-life of approximately 120-150 hours (5-6 days) due to its albumin-binding acyl side chain, which slows renal clearance. This pharmacokinetic profile enables sustained receptor activation and supports convenient once-weekly subcutaneous administration.

Survodutide Side Effects

The most common side effects are gastrointestinal and related to its potent GLP-1 activity. These include transient nausea, vomiting, diarrhea, constipation, and abdominal discomfort, which usually subside as the body adapts over several weeks. Less common effects may include injection site reactions, mild headache, or fatigue. The glucagon component does not typically cause hyperglycemia at therapeutic doses due to the counterbalancing GLP-1 effect.

Survodutide Contraindications/Precautionary Measures

Contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Should not be used by patients with a history of severe gastrointestinal disease (e.g., gastroparesis). Use with caution in individuals with pancreatitis, gallbladder disease, or severe renal impairment. Not recommended during pregnancy or breastfeeding.

Overdosage

Overdose would likely exacerbate the drug's known side effects, leading to severe and persistent nausea, vomiting, diarrhea, and potentially dehydration and electrolyte imbalances. In cases of severe overdose, hypoglycemia is a theoretical risk due to the combined incretin effects. There is no specific antidote; treatment involves discontinuation, supportive care, and management of symptoms. Medical attention should be sought immediately.

Survodutide Stack/Cycle

Survodutide can be strategically stacked with other peptides to enhance specific goals. For a powerful, synergistic fat-loss stack, combine with AOD 9604 5 mg to target stubborn fat. To support muscle preservation and anabolic signaling during a calorie deficit, add PEG MGF 5 mg. For improving metabolic health and insulin sensitivity at the cellular level, consider adding MOTS-c 10 mg. To address skin laxity that may follow rapid weight loss, GHK-Cu 50 mg can promote collagen synthesis. For those interested in other GLP-1 based therapies, Reta offers a triple-hormone mechanism.

Package Presentation

Your order arrives in discreet, secure packaging. Each box contains one sealed 2 mL glass vial, filled with 10 mg of pure, lyophilized Survodutide peptide powder from Peptide Hubs.

Storage

Store the unmixed, lyophilized powder in a refrigerator between 2°C and 8°C (36°F - 46°F) until reconstitution. Protect from light. Once reconstituted with bacteriostatic water, the solution must be refrigerated and used within the recommended timeframe (typically 4 weeks). Do not freeze the reconstituted solution.

Survodutide Referrers

Survodutide is a novel, once-weekly dual agonist that co-activates the GLP-1 and glucagon receptors. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, suppresses glucagon secretion, delays gastric emptying, and promotes satiety in the central nervous system. Concurrent glucagon receptor agonism increases energy expenditure by stimulating hepatic glycogenolysis and gluconeogenesis, while also promoting lipolysis and fatty acid oxidation. This dual agonism creates a synergistic "brake and accelerator" effect on metabolism: reducing caloric intake while increasing caloric burn, resulting in a significantly enhanced negative energy balance for weight loss and metabolic improvement.

Third-Party Lab Test

2026-01-12

View Result

10.21 mg